Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

30.84
-0.0900-0.29%
Pre-market: 31.650.8100+2.63%04:30 EDT
Volume:917.46K
Turnover:28.10M
Market Cap:3.71B
PE:-10.68
High:31.16
Open:30.36
Low:29.87
Close:30.93
Loading ...

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Business Wire
·
23 Apr

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Dow Jones
·
22 Apr

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
22 Apr

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

PR Newswire
·
17 Apr

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

GlobeNewswire
·
14 Apr

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

GlobeNewswire
·
14 Apr

Circio Enters Research Agreement with Lonza to Advance RNA Technology

TIPRANKS
·
11 Apr

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Business Wire
·
10 Apr

Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham

Dow Jones
·
09 Apr

Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1

MT Newswires Live
·
08 Apr

BRIEF-Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran

Reuters
·
08 Apr

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (Del-Desiran) for Treatment of Myotonic Dystrophy Type 1

THOMSON REUTERS
·
08 Apr

Avidity Biosciences Inc - Expects to Complete Phase 3 Harbor Study Enrollment in Mid-2025

THOMSON REUTERS
·
08 Apr

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

PR Newswire
·
08 Apr

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money

Insider Monkey
·
06 Apr

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Zacks
·
03 Apr

Avidity Biosciences’ Promising Progress in FORTITUDE Study Boosts Buy Rating

TIPRANKS
·
03 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Avidity Biosciences to Participate in Upcoming Investor Conference

PR Newswire
·
01 Apr

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy

MT Newswires Live
·
31 Mar